Demonstrates the protective effects of nano-selenium-enriched jujube polysaccharides on colitis in mice, indicating potential therapeutic benefits.
Jujube polysaccharides and nano‑selenium have gained attention for their bioactivity. This study used jujube polysaccharides to stabilize selenium nanoparticles (JP-SeNPs) via redox method. The optimized JP-SeNPs had an average size of 142.0 nm (PDI 0.1989), contained zero-valent selenium, showing no HepG2 toxicity at 5–40 μg/mL. In DSS-induced colitis mice, JP-SeNPs alleviated weight loss, disease activity, and colon shortening, reduced histopathological damage, restored goblet cells and tight junctions, and lowered colonic TNF-α, IL-1β, IFN-γ, and serum endotoxin. Cecal short-chain fatty acids (acetate, propionate, butyrate) rebounded. 16S rRNA sequencing revealed enhanced α-diversity, enrichment of butyrate-producers, and restored carbohydrate metabolism. JP-SeNPs ameliorate colitis via barrier repair, inflammation suppression, microbiota modulation, and SCFA promotion, supporting its development as a functional formulation. • Stable amorphous JP-SeNPs were synthesized. • JP-SeNPs alleviated DSS-colitis symptoms (weight loss, colon length, DAI). • JP-SeNPs suppress TNF-α, IL-1β, IFN-γ; repair barrier; reduce endotoxin. • JP-SeNPs modulate gut microbiota, increase SCFAs, and have low cytotoxicity.
No takes yet. Share an insight, caveat, or question.
Cui et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: